Compare Super Micro Computer Inc (SMCI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs BIO-TECHNE Corp — how do they compare? Super Micro Computer Inc trades at $30.35 (market cap $15.41B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Super Micro Computer Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| SMCI | TECH | |
|---|---|---|
Market Cap | $15.41B | $11.16B |
Sector | Technology | Health |
52-Week High | $60.71 | $72.12 |
52-Week Low | $20.53 | $43.31 |
Enterprise Value | $22.93B | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
